Active Filter(s):
Details:
Orsini Pharmaceutical Services has been selected by Ultragenyx Pharmaceutical as a limited distribution specialty pharmacy partner for Dojolvi (triheptanoin). Dojolvi™ is indicated as a source of calories and fatty acids for the treatment of molecularly confirmed LC-FAOD.
Lead Product(s): Triheptanoin
Therapeutic Area: Genetic Disease Product Name: Dojolvi
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Ultragenyx Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 10, 2020